Hematopoietic Stem Cell Transplantation Market is expected to reach US$ 15 Billion by the year 2033 at a CAGR of 8% | FMI fmiblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fmiblog.com Daily Mail and Mail on Sunday newspapers.
Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma.
Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.
Swetha Kambhampati, MD, discusses how findings from a subgroup analysis of investigating the use of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma may support the continued exploration of this agent in earlier lines of therapy.
Researchers at City of Hope were awarded $32.3 million from the CIRM to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia.